Who
Anthony C. Hooper
Director
Company insider
Files Form 4 as: Director, BeOne Medicines; Director, MannKind; EVP, Global Commercial Ops., Amgen; SVP ComOps Pres USJap Int, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 156
- Buys
- 1
- Sells
- 2
- Bought
- $108K
- Sold
- $385K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 7 Mar 2006
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —18,980 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —82,781 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,556 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $114K35,000 at $3.27 | filing |
| 1 Mar 2026filed 3 Mar 2026 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $114K35,000 at $3.27 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,750 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —10,985 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —52,854 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,571 at $0.00 | filing |
| 14 May 2025filed 16 May 2025 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $114K25,000 at $4.56 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,151 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —16,341 at $0.00 | filing |
| 15 May 2024filed 17 May 2024 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —35,047 at $0.00 | filing |
| 4 Feb 2024filed 5 Feb 2024 | MNKD MannKindPharmaceuticals | SEC FORM 4 Code A | $131K40,000 at $3.27 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ONC BeOne Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,975 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | ONC BeOne MedicinesBiotechnology | SEC FORM 4 Code A | —12,922 at $0.00 | filing |
| 25 May 2023filed 26 May 2023 | MNKD MannKindoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —47,393 at $0.00 | filing |
News
Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple SclerosisBMY · rttnews.com · 23 Oct 2026Bristol Myers Squibb Moves On Two Fronts: MS Cell Therapy Data And Tempus AI Expansion; Stock DownBMY · rttnews.com · 23 Oct 2026Better Dividend Stock to Buy and Hold: Pfizer or Bristol Myers Squibb?BMY · aol.com · 23 Oct 2026MannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head AnalysisMNKD · tickerreport.com · 22 Oct 2026Financial Analysis: MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · dailypolitical.com · 22 Oct 2026Comparing MannKind (NASDAQ:MNKD) & Iovance Biotherapeutics (NASDAQ:IOVA)MNKD · tickerreport.com · 15 Oct 2026
0 headlines in the last 90 days name Anthony C. Hooper; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.